Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia

Journal of Bone and Mineral Metabolism

Volumn 30, Issue 1, 2012, Pages 93-99

  Imanishi, Yasuo ^a   Hashimoto, Jun ^b   Ando, Wataru ^b   Kobayashi, Keisuke ^a   Ueda, Takafumi ^c   Nagata, Yuki ^a   Miyauchi, Akimitsu ^d   Koyano, Hajime M ^e   Kaji, Hiroshi ^f   Saito, Takatoshi ^g   Oba, Koichi ^h   Komatsu, Yasato ⁱ   Morioka, Tomoaki ^a   Mori, Katsuhito ^a   Miki, Takami ^a   Inaba, Masaaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d Miyauchi Medical Center   (Japan)

^e JUNTENDO UNIVERSITY   (Japan)

^f KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ KYOTO CITY HOSPITAL   (Japan)

Author keywords

ASARM peptide; FGF 23; MEPE; Oncogenic osteomalacia; Tumor induced osteomalacia

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN;

ADULT; AGED; ARTICLE; BONE DEMINERALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GIANT CELL TUMOR; HEMANGIOPERICYTOMA; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; ONCOGENIC OSTEOMALACIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS, CONNECTIVE TISSUE; PHOSPHOPROTEINS; YOUNG ADULT;

EID: 84858812989     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-011-0290-8     Document Type: Article

References (30)

1. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1-30 (Pubitemid 38031617)
2. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663 (Pubitemid 36459471)
3. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H, Econs MJ (2001) The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497-500 (Pubitemid 32207449)
4. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960 (Pubitemid 35316332)
5. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435 (Pubitemid 38787398)
6. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008 (Pubitemid 350224109)
7. Imanishi Y, Inaba M, Kawata T, Nishizawa Y (2009) Animal models of hyperfunctioning parathyroid diseases for drug development. Expert Opin Drug Discov 4:727-740
8. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505 (Pubitemid 32488266)
9. De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC (2002) Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:1102-1110 (Pubitemid 34535149)
10. White KE, Larsson TE, Econs MJ (2006) The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev 27:221-241
11. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R (2003) Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785-794 (Pubitemid 38057719)
12. Nakanishi R, Akiyama H, Kimura H, Otsuki B, Shimizu M, Tsuboyama T, Nakamura T (2008) Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass. J Bone Miner Res 23:271-277 (Pubitemid 351160041)
13. Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA Jr, Gagel RF, Hoff AO (2008) Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 14:1108-1114
14. Ishii A, Imanishi Y, Kobayashi K, Hashimoto J, Ueda T, Miyauchi A, Koyano HM, Kaji H, Saito T, Oba K, Komatsu Y, Kurajoh M, Nagata Y, Goto H, Wakasa K, Sugimoto T, Miki T, Inaba M, Nishizawa Y (2010) The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels. Calcif Tissue Int 86:455-462
15. Park YK, Unni KK, Beabout JW, Hodgson SF (1994) Oncogenic osteomalacia: a clinicopathologic study of 17 bone lesions. J Korean Med Sci 9:289-298
16. Kumar R (2000) Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone 27:333-338
17. Kobayashi K, Imanishi Y, Koshiyama H, Miyauchi A, Wakasa K, Kawata T, Goto H, Ohashi H, Koyano HM, Mochizuki R, Miki T, Inaba M, Nishizawa Y (2006) Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci 78:2295-2301
18. Nampei A, Hashimoto J, Hayashida K, Tsuboi H, Shi K, Tsuji I, Miyashita H, Yamada T, Matsukawa N, Matsumoto M, Morimoto S, Ogihara T, Ochi T, Yoshikawa H (2004) Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 22:176-184 (Pubitemid 38660947)
19. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y (2004) FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65:1943-1946 (Pubitemid 38591047)
20. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL (2000) MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54-68 (Pubitemid 30471121)
21. Argiro L, Desbarats M, Glorieux FH, Ecarot B (2001) Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 74:342-351 (Pubitemid 32675358)
22. Boskey AL, Chiang P, Fermanis A, Brown J, Taleb H, David V, Rowe PS (2010) MEPE's diverse effects on mineralization. Calcif Tissue Int 86:42-46
23. Addison WN, Nakano Y, Loisel T, Crine P, McKee MD (2008) MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 23:1638-1649
24. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA (2003) Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998-2007 (Pubitemid 36801442)
25. David V, Martin A, Hedge AM, Rowe PS (2009) Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 150:4012-4023
26. Bresler D, Bruder J, Mohnike K, Fraser WD, Rowe PS (2004) Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 183:R1-R9 (Pubitemid 40057594)
27. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18:2683-2688 (Pubitemid 47531195)
28. Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23:939-948 (Pubitemid 351768812)
29. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692 (Pubitemid 38057709)
30. Lu C, Huang S, Miclau T, Helms JA, Colnot C (2004) Mepe is expressed during skeletal development and regeneration. Histochem Cell Biol 121:493-499 (Pubitemid 38916437)